002038 Beijing Sl Pharmaceutical
- 8.47
- +0.02+0.24%
Beijing Sl Pharmaceutical News
Express News | Shuanglu Pharmaceutical: The antiallergic drug desloratadine has submitted a marketing application and is about to be approved for marketing
Express News | Shuanglu Pharmaceutical: Net profit of 70.1346 million yuan in the first quarter, a year-on-year decrease of 65.27%
“Jia Ling Lose Weight” has been trending for 4 days in a row. Will the number one investment theme in the Year of the Dragon be a comeback of the diet pill concept?
Under the popularity of the topic, the market speculates: will diet pills become the first investment theme in the Year of the Dragon?
Shuanglu Pharmaceutical (002038.SZ): 2023 net profit pre-increased by 66%-100%
Gelonghui, January 26 | Shuanglu Pharmaceutical (002038.SZ) announced its 2023 annual results forecast. Net profit and profit attributable to shareholders of listed companies during the reporting period was about 39 million yuan to 47 million yuan, an increase of about 66%-100% over the same period of the previous year; net profit after deducting non-recurring profit and loss was about 20 million yuan to 250 million yuan, an increase of about 40%-75% over the same period last year; basic earnings per share were about 0.38 yuan/share - 0.46 yuan/share. During the reporting period, the company's net profit attributable to shareholders of listed companies increased significantly. The first is the company's non-recurring losses
Gene therapy may open a new chapter in the pharmaceutical field, and the industry has broad prospects for growth
① Gene therapy developer VoyagerTherapeutics has reached a strategic cooperation and licensing agreement with Novartis Pharmaceuticals subsidiaries to advance novel gene therapies for Huntington's disease and spinal muscular atrophy. ② The agency expects the global gene editing market to reach US$36.61 billion by 2030, with a compound annual growth rate of 22.3%.
A-share review: the three major indices fell slightly, and sectors such as diet pills, wind power equipment and auto parts fell
Greenway, December 7 | In US dollars, China's exports in November increased 0.5% year on year, exceeding expectations; the main A-share index opened low today and rebounded in the afternoon. At the close, the Shanghai Index fell 0.09% to 2,966 points, the Shenzhen Stock Exchange Index fell 0.14%, and the GEM Index fell 0.25%. Nearly 3,200 shares in the two markets fell, trading for 820.2 billion yuan throughout the day, and the net purchase of capital going north was 373 million yuan. On the market, the spatial computing sector rose sharply in the afternoon, and many stocks such as Guomai Culture rose and stopped; Google launched the artificial intelligence model Gemini, artificial intelligence concept stocks rose, AIGC led the way, and many stocks such as Netda Software rose and stopped
The National Health and Health Commission suggests getting the influenza vaccine as soon as possible, and sorting out China's influenza vaccine market pattern and enterprises
① At present, influenza vaccines from several domestic manufacturers have been approved for the market, of which 11 manufacturers have supplied them during the 2022-2023 influenza season; ② The Zhongtai Securities Research Report points out that with the arrival of the influenza season, it is recommended to pay attention to investment opportunities for relevant testing, vaccine and drug companies.
Shuanglu Pharmaceutical (002038.SZ): Currently, sales of products such as oseltamivir, thymus pentapeptide, and interleukin-2 have increased markedly
Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Does the company have oseltamivir and azithromycin-related products?” The company replied that at present, sales of the company's products such as oseltamivir, thymus pentapeptide, and interleukin-2 have increased markedly.
Shuanglu Pharmaceutical (002038.SZ): Gicabine is still in phase III clinical research
Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Please tell me about the development progress of your gigacabine and febusil in China?” The company replied that gigabine is still in phase III clinical research, febusta has been conditionally listed in the US, and that the domestic listing application is under normal review.
Shuanglu Pharmaceutical (002038.SZ): Nippon Pharmaceutical has now completed phase III follow-up of all test subjects, and is expected to submit registration applications next year
Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Is the company's GLP-1 formulation expected to be registered this year?” The company replied that the Japanese drug has now completed phase III clinical trials and is in the clinical data collation stage. Currently, it has completed follow-up of all phase III subjects, and it is expected that registration applications will be submitted next year.
Weight loss drug concept stocks rose again, Changshan Pharmaceutical rose nearly 10%
Gelonghui November 23 | Changshan Pharmaceutical rose nearly 10%, Shuanglu Pharmaceutical and Puli Pharmaceutical rose more than 5%, and Hanyu Pharmaceutical, Haofan Biotech, Dezhan Health, and Notai Biotech followed suit. According to the news, the European Medicines Agency (EMA) recently stated in a letter published on its website that it and Novo Nordisk expect that the shortage of Ozempic (GLP-1 drug semeglutide) and Victoza liraglutide will worsen in the fourth quarter of 2023, and there will still be a shortage of Ozempic supply in the EU market in 2024.
The diet drug sector rebounded, and Changshan Pharmaceutical rose more than 8%
Gelonghui November 22 | Changshan Pharmaceutical surged 8%, while Shuanglu Pharmaceutical, Hanyu Pharmaceutical, Zhongsheng Pharmaceutical, and Dezhan Health rose. According to the news, on Tuesday (November 21) local time, the European Medicines Agency (EMA) stated in a letter published on its website that it and Novo Nordisk expect that the shortage of Ozempic (GLP-1 drug semeglutide) and Victoza liraglutide will worsen in the fourth quarter of 2023, and there will still be a shortage of Ozempic supply in the EU market in 2024.
Shuanglu Pharmaceutical (002038.SZ): The company has no Smegalotide R&D
Gelonghui November 20 | Shuanglu Pharmaceutical (002038.SZ) said on the investor interactive platform that the company has not developed simeglutide, but the company's GLP-1 long-acting drug, duracylotide, has now completed phase III clinical enrollment and is expected to complete clinical research in the first half of next year; the GLP-1 preparation, liraglutide, is in the clinical data compilation stage. It is expected that all phase III participants will be followed up. It is expected that registration applications will be submitted next year.
Shuanglu Pharmaceutical (002038.SZ): No separate weight loss clinical studies were conducted in the GLP-1 clinical trials
On November 20, Gelonghui, on the investor interactive platform, some investors asked Shuanglu Pharmaceutical (002038.SZ), “Has the GLP-1 project currently being developed approved for obesity and overweight indications? “Don't answer by using methods such as GLP1 for lowering sugar and weight loss, etc.” The company replied that in the clinical trials of the company's GLP-1 projects, no separate weight loss clinical studies were conducted, but weight changes were observed as secondary efficacy indicators, and no marketing application has been submitted so far.
Shuanglu Pharmaceutical (002038.SZ): Long-acting libiotic has been marketed for sale, and Dapagliflozin has not yet been produced or marketed
Glonghui November 20: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “When will your long-term whitening and Dagliflogenin plans start selling?” The company replied that the company's long-term libiotic is already on the market, and Daglizine has not yet been produced or marketed.
Shuanglu Pharmaceutical (002038.SZ): Three products plan to win the bid for centralized national drug procurement
Shuanglu Pharmaceutical (002038.SZ) issued an announcement. The company participated in the joint procurement office on November 6, 2023...
[BT Financial Report Instantaneous Analysis] Shuanglu Pharmaceutical's 2023 Quarterly Report: The balance ratio has declined, net profit has increased significantly, and net cash flow has decreased
This financial report was announced on 2023-10-25 18:30:26 Shuanglu Pharmaceutical (stock code: 002038) is a pharmaceutical biotechnology enterprise focusing on the research, development, production and operation of genetic engineering and related drugs. The company's main business covers the fields of oncology, cardiovascular and cerebrovascular, endocrine, liver disease, nephropathy, and anti-infection and trauma repair. It has multiple production bases, covering various product categories such as tablets, hard capsules, granules, injections, freeze-dried powder injections, biochemical APIs, therapeutic biological products, psychotropic drugs, etc. In terms of assets and liabilities, Shuanglu Pharmaceutical in the third quarter of 2023
Weight loss drug concept stocks fell, and Shuanglu Pharmaceutical fell more than 8%
Gelonghui, October 26 | Shuanglu Pharmaceutical fell more than 8%, Hanyu Pharmaceutical fell more than 5%, and Changshan Pharmaceutical, Haofan Biotech, Nuotai Biotech, and Borui Pharmaceutical fell more than 3%.
Shuanglu Pharmaceutical (002038.SZ) released results for the first three quarters, with net profit of 318 million yuan, an increase of 33.46%
Shuanglu Pharmaceutical (002038.SZ) released its report for the third quarter of 2023, and achieved operating income of 7.7 in the first three quarters...
Beijing SL Pharmaceutical Gets Nod to Trial Anti-Hepatitis C Drug; Shares Drop 10%
Beijing SL Pharmaceutical (SHE:002038) will conduct clinical trials for MBT-1608 tablets after obtaining the approval of China's National Medical Products Administration. The Chinese pharmaceutical co
Analysis
Price Target
No Data
